Newest Vascular Access Technology
We Can't Keep Using the Same Materials and Expecting Better Outcomes.
MIMIX® technology in action
*Data on file at Access Vascular. Reduction of thrombus accumulation was evaluated using in vitro and in vivo models. Pre-clinical in vitro/in vivo evaluations do not necessarily predict clinical performance with respect to thrombus formation.
LEARN MORE ABOUT MIMIX TECHNOLOGY
AVI has produced a whitepaper outlining further details on our unique technology, how it works, and both in vitro and in vivo data.
An average of 97% less thrombus accumulation on its surface (based on platelet count)* compared to a standard polyurethane catheter.
Testing includes an FDA-recognized blood flow loop test conducted by Thrombodyne Inc and placement of HydroPICC® devices in ovine models for 14 or 28 days.
*No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
Are you interested in learning more about our products?
